Circle Pharma announces $92.5 million Series E financing led by The Column Group to advance their Cyclin D1 program into clinical development.
Amount Raised
$92.5 Million
Round Type
Series E
South San FranciscoHealthcareHealth CareInvestors
Description
Circle Pharma, a clinical-stage biopharmaceutical company, has successfully raised $92.5 million in an oversubscribed Series E financing. The funding was led by The Column Group with participation from existing and new investors including Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly. The proceeds will be used to advance their first-in-class Cyclin D1 program. This financing marks a significant step forward in their efforts to develop targeted macrocycle therapeutics for cancer.
Who to call at Circle Pharma, and when
A new round usually means Circle Pharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Circle Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Circle Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Circle Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Circle Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Circle Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.